Riskpilot← Back to searchSign inGet full accessGravidklinikken ApS
APSActiveCVR 38613642Stormgade 15, st. tvNursing and midwifery activities · NACE 8694Est. 20175 employeeswww.gravidklinikken.dk
Revenue 2025
DKK 1,2M
+36% vs 2024
EBITDA margin
41.6%
-5% vs 2024
Equity ratio
64.2%
Financial strength
Net profit 2025
DKK 279K
-8% vs 2024
| Revenue | DKK 1,2M | +36% |
| EBITDA | DKK 501K | -5% |
| Net profit | DKK 279K | -8% |
| Total assets | DKK 519K | -18% |
| Equity | DKK 333K | +116% |
| Employees | 5 | — |
Legal name
Gravidklinikken ApS
CVR number
38613642
Legal form
Anpartsselskab
NACE code
8694 · Nursing and midwifery activities
Founded
2. maj 2017
Share capital
DKK 50.000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Selskabet tegnes af Direktionen
Company purpose
Selskabets formål er at drive virksomhed med ultralydsscanninger og andre ydelser til kvinder i forbindelse med graviditet og hermed forbundet virksomhed.
Address
Stormgade 15, st. tv
Email
info@gravidklinikken.dk
Website
www.gravidklinikken.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 735 | 373 | 707 | 887 | 1.204 |
| Staff expenses | -283 | -103 | -265 | -329 | -325 |
| EBITDA | 435 | 260 | 425 | 530 | 501 |
| Depreciation & amort. | -0 | -0 | -72 | -117 | -117 |
| EBIT | 435 | 260 | 352 | 413 | 384 |
| Net financials | -6 | -3 | -13 | -23 | -15 |
| Profit before tax | 429 | 256 | 339 | 390 | 369 |
| Tax | 93 | 59 | 82 | 88 | 90 |
| Net profit | 335 | 198 | 257 | 302 | 279 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 556 | 226 | 735 | 632 | 519 |
| Equity | 399 | 86 | 262 | 154 | 333 |
| Long-term debt | 0 | 0 | 321 | 0 | 0 |
| Short-term debt | 158 | 139 | 143 | 459 | 166 |
| Total debt | 158 | 139 | 464 | 459 | 166 |
EBITDA margin
41.6%
This company
15.8%
Market median
+163% vs market
20212025
Equity ratio
64.2%
This company
38.2%
Market median
+68% vs market
20212025
Return on equity
83.7%
This company
18.4%
Market median
+355% vs market
20212025
Net profit margin
23.2%
This company
8.1%
Market median
+186% vs market
20212025
Asset turnover
2.32×
This company
1.12×
Market median
+107% vs market
20212025
Debt / equity
0.56×
This company
0.62×
Market median
+10% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via CVR / Virk · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via CVR / Virk · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via CVR / Virk · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via CVR / Virk · Period 2020-07-01 – 2021-06-30
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
JF Management | Management | 2024 |
CF Chief Executive Officer | Chief Executive Officer | 2024 |
LB Founder | Founder | 2017 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 50–66.65% | 50–66.65% | 2021 | |
| Individual | 25–33.32% | 25–33.32% | 2022 | |
| Individual | 20–24.99% | 20–24.99% | 2022 | |
| Company | 50–66.65% | 50–66.65% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
248DK Holding ApS
Gravidklinikken ApS Board members of Gravidklinikken ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jesper Frosch Holmager Sloth | Management | 0 companies |
| Camilla Frosch Holmager Sloth | Chief Executive Officer | 0 companies |
| Line Biltoft Wormstrup | Founder | 0 companies |